Figure 1
Figure 1. PFS and OS for patients treated at the MTD. (A) PFS and (B) OS of the 67 lenalidomide-refractory MM patients treated with REP at the MTD.

PFS and OS for patients treated at the MTD. (A) PFS and (B) OS of the 67 lenalidomide-refractory MM patients treated with REP at the MTD.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal